Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

PHASE1SuspendedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 9, 2021

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

ORIN1001

Oral tablet - ORIN1001

DRUG

Placebo

Oral tablet - placebo

Trial Locations (11)

27710

Duke University Hospital, Durham

32224

Mayo Clinic Hospital, Jacksonville

32503

Avanza Medical Research, Pensacola

33704

Coastal Pulmonary and Critical Care, St. Petersburg

33765

St. Francis Sleep, Allergy & Lung Institute, Clearwater

45220

University of Cincinnati, Cincinnati

52242

University of Iowa Hospital, Iowa City

60153

Loyola University Medical Center, Maywood

63401

Hannibal Clinic, Hannibal

02747

Infinity Medical Research, North Dartmouth

03766

Dartmouth Hitchcock Medical Center, Lebanon

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Vanderbilt University

OTHER

lead

Orinove, Inc.

INDUSTRY